再鼎医药商业化加速 营收四年增19.5倍持续减亏

长江商报
14 Nov 2024

长江商报消息视觉中国图创新药企再鼎医药(ZLAB.US、09688.HK)持续减亏。11月12日晚间,再鼎医药发布三季报,财报显示,今年第三季度公司产品收入净额为1.018亿美元,2023年同期为6920万美元,同比增长47%。这一增长主要是由于卫伟迦、则乐和纽再乐销售额的增加。截至目前,再鼎医药共有五款药物上市实现商业化,分别为则乐、爱普盾、纽再乐、擎乐和卫伟迦。长江商报记者注意到,2019年是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10